panitumumab
Amgen Sees Strong Growth for Precision Oncology Drugs in Q3
Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.
The firm's bispecific T-cell engager Blincyto and KRAS inhibitor Lumakras each provided double-digit sales growth in Q2.
Amgen's Lumakras Reports Double-Digit Sales Growth in Q1
The KRAS inhibitor recorded $82 million in sales in Q1 2024, up 11 percent compared to $74 million during the year-ago period.
The bispecific immunotherapy Blincyto saw the largest increase in Q4 2023 revenue, a 47 percent jump from the same period in 2022.
Blincyto sales continue to grow following positive data last year in acute lymphoblastic leukemia and an update to NCCN guidelines for pediatric patients.
Jun 1, 2023